display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L1 - all population
nivolumab plus ipilimumab CheckMate 069 ... CheckMate 067 ... CheckMate 067 ...

Study type: